Beovu

RSS

brolucizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Beovu is a medicine used to treat adults with the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling.

The macula provides central vision that is needed to see detail for everyday tasks such as driving, reading and recognising faces. The diseases cause the gradual loss of the central part of a person’s vision.

Beovu contains the active substance brolucizumab.

This EPAR was last updated on 18/02/2020

Authorisation details

Product details
Name
Beovu
Agency product number
EMEA/H/C/004913
Active substance
brolucizumab
International non-proprietary name (INN) or common name
brolucizumab
Therapeutic area (MeSH)
Wet Macular Degeneration
Anatomical therapeutic chemical (ATC) code
S01
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Novartis Europharm Limited 
Date of issue of marketing authorisation valid throughout the European Union
13/02/2020
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4
Ireland

Product information

13/02/2020 Beovu - EMEA/H/C/004913 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Assessment history

How useful was this page?

Add your rating
Average
1 rating